07.10.2013 • NewsBiogenBiogen IdecMS treatment

Biogen's New MS Drug Maintains Efficacy Long Term -Study

Biogen Idec's hot-selling new multiple sclerosis drug Tecfidera remained effective for patients taking the medicine for at least four years with no new safety problems, according to interim data from a long-term study. Tecfidera, which analysts expect to eventually dominate the MS market, had sales of $192 million in its first quarter on the market - nearly triple average Wall Street expectations. The Endorse extension study followed patients who had taken part in two pivotal Phase III trials that led to the U.S. approval of Tecfidera.

 

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.